Haitao Zhao

机构：Dalian Medical University, Chinese Academy of Medical Sciences & Peking Union Medical College, Huawei Technologies (China), Peking Union Medical College Hospital, University of North Carolina at Pembroke, Second Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, The Affiliated Yongchuan Hospital of Chongqing Medical University, Huaiyin Normal University, Chongqing Medical University · ORCID：0000-0002-3444-8044

发表论文 557 篇 · 总被引 16201 次 · h-index 60

代表论文

• Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial (2025 · The Lancet · 被引 49)
• FAD synthase confers ferroptosis resistance and restrains CD8+ T cell recruitment in hepatocellular carcinoma (2025 · Nature Communications · 被引 7)
• Adjuvant TACE Improves Prognosis After Resection in Dual-Phenotype Hepatocellular Carcinoma: A Propensity Score-Matched Study (2025 · Journal of Hepatocellular Carcinoma · 被引 4)
• High-dosage human albumin infusion may be superior for hypervolemic hyponatremia in cirrhosis with ascites (2025 · Expert Review of Gastroenterology & Hepatology · 被引 2)
• Dynamic urinary proteomics integrates single-cell and spatial transcriptomics to reveal tumour microenvironment and predict immunotherapy response in biliary tract cancer (2025 · Gut · 被引 2)
• Local therapy overcomes primary resistance to target-immunotherapy combination in unresectable hepatocellular carcinoma (2025 · Cancer Immunology Immunotherapy · 被引 2)